405 related articles for article (PubMed ID: 30194658)
21. Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy.
Rojas KE; Fortes TA; Borgen PI
Breast Cancer Res Treat; 2019 Apr; 174(2):307-313. PubMed ID: 30536119
[TBL] [Abstract][Full Text] [Related]
22. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
[TBL] [Abstract][Full Text] [Related]
23. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
[TBL] [Abstract][Full Text] [Related]
24. The molecular journey from ductal carcinoma in situ to invasive breast cancer.
Wiechmann L; Kuerer HM
Cancer; 2008 May; 112(10):2130-42. PubMed ID: 18383519
[TBL] [Abstract][Full Text] [Related]
25. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease?
Evans AJ; Pinder SE; Ellis IO; Wilson AR
J Med Screen; 2001; 8(3):149-51. PubMed ID: 11678555
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast.
Shibuya R; Suzuki T; Miki Y; Yoshida K; Moriya T; Ono K; Akahira J; Ishida T; Hirakawa H; Evans DB; Sasano H
Endocr Relat Cancer; 2008 Mar; 15(1):113-24. PubMed ID: 18310280
[TBL] [Abstract][Full Text] [Related]
27. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
28. Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression.
Carraro DM; Elias EV; Andrade VP
Biosci Rep; 2014 Feb; 34(1):. PubMed ID: 27919043
[TBL] [Abstract][Full Text] [Related]
29. Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It?
Cserni G; Sejben A
Pathol Oncol Res; 2020 Apr; 26(2):665-671. PubMed ID: 31776839
[TBL] [Abstract][Full Text] [Related]
30. Spindle cell ductal carcinoma in situ. An unusual variant of ductal intra-epithelial neoplasia that simulates ductal hyperplasia or a myoepithelial proliferation.
Farshid G; Moinfar F; Meredith DJ; Peiterse S; Tavassoli FA
Virchows Arch; 2001 Jul; 439(1):70-7. PubMed ID: 11499843
[TBL] [Abstract][Full Text] [Related]
31. Predictive values of BI-RADS(®) magnetic resonance imaging (MRI) in the detection of breast ductal carcinoma in situ (DCIS).
Badan GM; Piato S; Roveda D; de Faria Castro Fleury E
Eur J Radiol; 2016 Oct; 85(10):1701-1707. PubMed ID: 27666605
[TBL] [Abstract][Full Text] [Related]
32. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer.
Luiten JD; Voogd AC; Luiten EJT; Duijm LEM
Breast Cancer Res Treat; 2017 Nov; 166(1):307-314. PubMed ID: 28748346
[TBL] [Abstract][Full Text] [Related]
33. 3-D tissue modelling and virtual pathology as new approaches to study ductal carcinoma in situ.
Booth ME; Nash CE; Roberts NP; Magee DR; Treanor D; Hanby AM; Speirs V
Altern Lab Anim; 2015 Dec; 43(6):377-83. PubMed ID: 26753940
[TBL] [Abstract][Full Text] [Related]
34. Intratumor Heterogeneity of Synchronous
Kim H; Gim JA; Kim CY; Kim A
Anticancer Res; 2021 Aug; 41(8):3779-3787. PubMed ID: 34281837
[TBL] [Abstract][Full Text] [Related]
35. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena.
Kopans DB; Rafferty E; Georgian-Smith D; Yeh E; D'Alessandro H; Moore R; Hughes K; Halpern E
Cancer; 2003 Jun; 97(12):2951-9. PubMed ID: 12784329
[TBL] [Abstract][Full Text] [Related]
36. The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.
Elshof LE; Schaapveld M; Rutgers EJ; Schmidt MK; de Munck L; van Leeuwen FE; Wesseling J
Breast Cancer Res; 2017 Mar; 19(1):26. PubMed ID: 28274272
[TBL] [Abstract][Full Text] [Related]
37. Evolving Treatment Paradigms for Low-Risk Ductal Carcinoma In Situ: Imaging Needs.
Nguyen DL; Greenwood HI; Rahbar H; Grimm LJ
AJR Am J Roentgenol; 2024 Mar; 222(3):e2330503. PubMed ID: 38090808
[TBL] [Abstract][Full Text] [Related]
38. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
39. Should breast screening programmes limit their detection of ductal carcinoma in situ?
Evans AJ; Blanks RG
Clin Radiol; 2002 Dec; 57(12):1086-9. PubMed ID: 12475533
[TBL] [Abstract][Full Text] [Related]
40. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.
Martínez-Pérez C; Turnbull AK; Ekatah GE; Arthur LM; Sims AH; Thomas JS; Dixon JM
Cancer Treat Rev; 2017 Apr; 55():163-172. PubMed ID: 28402908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
